CROMSOURCE, the contract research organisation (CRO) formed from the acquisition of Belgium’s MSOURCE by Italian company CROM in April 2011, has opened new offices in Paris, France.
Dr Christian Milla, global head of the Medical Division and director of operations for France, said CROMSOURCE had been stepping up its activities in the market year on year and expected further growth in the future.
There are also benefits to clients from CROMSOURCE being on the French Ministry of Research’s list of approved CROs, he noted.
Many of these customers will be able to claim “significant” tax credits for research and development activities conducted by CROMSOURCE on their behalf.
“With more than 33% of international Phase II and III studies being performed here, France is a key strategic country for CROMSOURCE,” Milla stated.
High demand
Margherita Mosconi, director of client project development, cited high demand in France from smaller biopharmaceutical and medical-technology companies for “knowledgeable partners who can support them and keep within timelines and budgets”.
These clients “appreciate the CROMSOURCE philosophy of acting as an expert addition to their team”, Mosconi added.
